- Home
- BMRN vs SF Comparison
BMRN vs SF Comparison
Compare BMRN & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMRN | SF |
|---|---|---|
| Founded | 1996 | 1890 |
| Country | United States | United States |
| Employees | N/A | 9000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 11.2B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | BMRN | SF |
|---|---|---|
| Price | $60.82 | $82.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 7 |
| Target Price | $88.22 | ★ $90.33 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 05-04-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.76% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $1,313,646,000.00 | N/A |
| Revenue This Year | $15.02 | $14.58 |
| Revenue Next Year | $12.23 | $8.03 |
| P/E Ratio | $109.87 | ★ $20.53 |
| Revenue Growth | ★ 17.62 | N/A |
| 52 Week Low | $49.26 | $67.81 |
| 52 Week High | $66.28 | $134.74 |
Technical Indicators
Market Signals| Indicator | BMRN | SF |
|---|---|---|
| Relative Strength Index (RSI) | 63.18 | 72.59 |
| Support Level | $54.24 | $68.36 |
| Resistance Level | $61.92 | $83.82 |
| Average True Range (ATR) | 1.40 | 1.82 |
| MACD | -0.07 | 0.60 |
| Stochastic Oscillator | 96.63 | 94.28 |
Price Performance
Historical ComparisonAbout BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About SF Stifel Financial Corporation
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from trading and investment banking.